Susquehanna Fundamental Investments’s Neurocrine Biosciences NBIX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$240K	Buy	+1,422	New	+$211K	﹤0.01%	675
2025 Q1	–	Sell	-114,661	Closed	-$15.7M	–	1175
2024 Q4	$15.7M	Buy	+114,661	New	+$14.2M	0.22%	110
2024 Q2	$509K	Buy	+3,695	New	+$507K	0.01%	688
2021 Q4	–	Sell	-47,618	Closed	-$4.57M	–	1659
2021 Q3	$4.57M	Buy	47,618 +40,168	+539%	+$3.79M	0.08%	317
2021 Q2	$725K	Sell	7,450 -13,966	-65%	-$1.34M	0.01%	1006
2021 Q1	$2.08M	Sell	21,416 -396	-2%	-$41.5K	0.04%	630
2020 Q4	$2.09M	Buy	+21,812	New	+$2.11M	0.04%	607

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Susquehanna Fundamental Investments's NBIX Position: Q2 2026 in Review

Susquehanna Fundamental Investments opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 1,422 shares worth $240K. The stake represents ﹤0.01% of the portfolio and ranks #675 among its holdings. This is a return to the name: Susquehanna Fundamental Investments previously reported a position in NBIX as recently as Q4 2024.

Susquehanna Fundamental Investments first reported a position in NBIX in Q4 2020 and has held it in 7 quarters since. The position peaked at $15.7M in Q4 2024. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Susquehanna Fundamental Investments held 1,422 shares of Neurocrine Biosciences worth $240K as of Q2 2026.
Neurocrine Biosciences was a new Susquehanna Fundamental Investments position in Q2 2026.
Neurocrine Biosciences made up ﹤0.01% of Susquehanna Fundamental Investments's portfolio in Q2 2026, its #675 holding.
Susquehanna Fundamental Investments first reported a position in Neurocrine Biosciences in Q4 2020 and has held it in 7 quarters since.
Susquehanna Fundamental Investments's Neurocrine Biosciences position peaked at $15.7M in Q4 2024.
781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2026, filed 14 Aug 2026.